$1.39 Billion is the total value of Novo Holdings A/S's 19 reported holdings in Q2 2015. The portfolio turnover from Q1 2015 to Q2 2015 was 700.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TBRA | New | TOBIRA THERAPEUTICS INC | $46,513,000 | – | 2,696,405 | +100.0% | 3.34% | – |
| ADAP | New | ADAPTIMMUNE THERAPEUTICS PLCsponds adr | $32,290,000 | – | 1,761,567 | +100.0% | 2.32% | – |
| CLCD | New | COLUCID PHARMACEUTICALS INC | $27,203,000 | – | 3,056,563 | +100.0% | 1.96% | – |
| TKAI | Buy | TOKAI PHARMACEUTICALS INC | $16,469,000 | +23.1% | 1,238,252 | +4.6% | 1.18% | +4.0% |
| HTGM | New | HTG MOLECULAR DIAGNOSTICS INC | $14,274,000 | – | 1,280,185 | +100.0% | 1.03% | – |
| New | INVUITY INC | $10,457,000 | – | 740,616 | +100.0% | 0.75% | – | |
| GKOS | New | GLAUKOS CORP | $2,174,000 | – | 75,000 | +100.0% | 0.16% | – |
| XENT | Exit | INTERSECT ENT INC | $0 | – | 0 | +100.0% | 0.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VANGUARD INDEX FDS | 41 | Q3 2022 | 64.7% |
| INOGEN INC | 34 | Q2 2022 | 68.8% |
| VANGUARD INTL EQUITY INDEX F | 29 | Q4 2016 | 37.6% |
| AMICUS THERAPEUTICS INC | 22 | Q3 2023 | 4.1% |
| AKEBIA THERAPEUTICS INC | 21 | Q3 2020 | 4.8% |
| VERONA PHARMA PLC | 21 | Q2 2022 | 1.9% |
| CORVUS PHARMACEUTICALS INC | 20 | Q4 2020 | 7.1% |
| INSPIRE MED SYS INC | 20 | Q3 2023 | 1.8% |
| CABLE ONE INC | 19 | Q3 2023 | 9.7% |
| FLEXION THERAPEUTICS INC | 19 | Q3 2021 | 4.7% |
View Novo Holdings A/S's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyteir Therapeutics, Inc. | August 03, 2023 | 1,547,136 | 4.4% |
| Disc Medicine, Inc. | June 28, 2023 | 1,090,772 | 4.8% |
| Galera Therapeutics, Inc. | June 28, 2023 | 2,100,000 | 4.9% |
| VectivBio Holding AGSold out | May 26, 2023 | 0 | 0.0% |
| LanzaTech Global, Inc. | February 17, 2023 | 15,814,845 | 8.1% |
| Bolt Biotherapeutics, Inc.Sold out | January 04, 2023 | 0 | 0.0% |
| Arcellx, Inc. | December 12, 2022 | 1,750,000 | 4.0% |
| MINERVA SURGICAL INC | November 03, 2022 | 1,322,473 | 4.5% |
| Milestone Pharmaceuticals Inc. | October 24, 2022 | 1,378,538 | 4.6% |
| Galecto, Inc. | September 30, 2022 | 2,497,791 | 9.8% |
View Novo Holdings A/S's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-14 |
| SC 13G/A | 2024-05-14 |
| 144 | 2024-05-10 |
| SC 13D/A | 2024-03-28 |
| 4 | 2024-03-25 |
| SC 13D/A | 2024-03-25 |
| 4 | 2024-03-20 |
| SC 13D/A | 2024-03-20 |
| 144 | 2024-03-18 |
View Novo Holdings A/S's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.